Literature DB >> 2858145

Precurarization with vecuronium and pancuronium in awake, healthy volunteers: the influence on neuromuscular transmission and pulmonary function.

J Engbaek, P Howardy-Hansen, H Ording, J Viby-Mogensen.   

Abstract

The influence of pretreatment with pancuronium and vecuronium on the neuromuscular transmission was compared in 24 healthy, awake, non-premedicated volunteers using train-of-four (TOF) nerve stimulation and measurement of respiratory frequency, vital capacity, inspiratory force and peak expiratory flow (PEF). The subjects were randomly allocated to one of three groups. Each subject received one dose of pancuronium and one dose of vecuronium: Group I pancuronium 0.01 mg/kg and vecuronium 0.005 mg/kg; Group II pancuronium 0.01 mg/kg and vecuronium 0.01 mg/kg and Group III pancuronium 0.01 mg/kg and vecuronium 0.015 mg/kg intravenously. The median TOF ratio decreased significantly in Groups I and II following both pancuronium and vecuronium. The TOF ratio following vecuronium in Group II was significantly lower compared to the TOF ratio following vecuronium in Group I. Only PEF decreased significantly in Group I following pancuronium and in Group II following both pancuronium and vecuronium. There was no significant difference between Group I and Group II regarding the number of subjects with signs or symptoms of partial neuromuscular blockade. Following vecuronium 0.005 mg/kg, one subject was unable to swallow and the twitch height decreased to 0.25. In Group II one subject was unable to lift her head and had difficulty in swallowing following pancuronium 0.01 mg/kg. Only four subjects entered Group III because of an unacceptably high frequency of signs and symptoms of partial neuromuscular blockade and a decrease in median TOF ratio to 0.64 following vecuronium. The subjects felt it difficult to swallow, and one subject could just sustain head lift for 10 s following vecuronium 0.015 mg/kg.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2858145     DOI: 10.1111/j.1399-6576.1985.tb02170.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  10 in total

1.  [Muscle relaxants in Germany 2005: a comparison of application customs in hospitals and private practices].

Authors:  H Fink; G Geldner; T Fuchs-Buder; R Hofmockel; K Ulm; B Wallek; M Blobner
Journal:  Anaesthesist       Date:  2006-06       Impact factor: 1.041

2.  Efficacy of priming with atracurium.

Authors:  M Sosis
Journal:  Can J Anaesth       Date:  1987-05       Impact factor: 5.063

Review 3.  Onset of action of relaxants.

Authors:  F Donati
Journal:  Can J Anaesth       Date:  1988-05       Impact factor: 5.063

4.  Priming with nondepolarizing relaxants for rapid tracheal intubation: a double-blind evaluation.

Authors:  R K Baumgarten; C E Carter; W J Reynolds; J L Brown; H V DeVera
Journal:  Can J Anaesth       Date:  1988-01       Impact factor: 5.063

5.  The priming saga: where do we stand now?

Authors:  F Donati
Journal:  Can J Anaesth       Date:  1988-01       Impact factor: 5.063

6.  Negative pressure pulmonary oedema: a potential hazard of muscle relaxants in awake infants.

Authors:  L O Warner; J D Martino; P J Davidson; T P Beach
Journal:  Can J Anaesth       Date:  1990-07       Impact factor: 5.063

7.  The optimal priming dose for atracurium.

Authors:  M Naguib; M Abdullatif; G H Absood
Journal:  Can Anaesth Soc J       Date:  1986-07

8.  Rapid induction sequence with vecuronium: should we intubate after 60 or 90 seconds?

Authors:  A Boulanger; J F Hardy; Y Lepage
Journal:  Can J Anaesth       Date:  1990-04       Impact factor: 5.063

9.  Subparalyzing Doses of Rocuronium Reduce Muscular Endurance without Detectable Effect on Single Twitch Height in Awake Subjects.

Authors:  Jan Gelberg; Peter Bentzer; David Grubb
Journal:  Anesthesiol Res Pract       Date:  2019-05-02

10.  Vigilance: the behavioral impact of quantitative monitoring on administration and antagonism of neuromuscular blocking agents.

Authors:  Anastasia D Grivoyannis; Virginia Tangel; Cynthia A Lien
Journal:  J Clin Monit Comput       Date:  2021-06-22       Impact factor: 1.977

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.